Celldex Therapeutics
Biotech that ran one of the early GPNMB ADCs in triple-negative breast cancer, which failed, and has since pivoted to mast-cell (KIT) antibodies for allergic disease.
Glembatumumab vedotin (CDX-011, GPNMB-directed MMAE ADC) did not meet its primary endpoint in the METRIC trial in GPNMB-overexpressing metastatic TNBC (2018). Celldex's lead asset is now barzolvolimab, an anti-KIT antibody in phase 3 for chronic urticaria; its oncology footprint is historical but instructive for ADC target selection.
Pages like this
not linked directly; found by shared links- TargetLIV-1 (SLC39A6)
Shares Antibody-drug conjugate (ADC), Triple-negative breast cancer (TNBC).
- ProductTrastuzumab duocarmazine
Shares Antibody-drug conjugate (ADC) and the tag failure.
- ProductTusamitamab ravtansine
Shares Antibody-drug conjugate (ADC) and the tag failure.
- ProductRovalpituzumab tesirine
Shares Antibody-drug conjugate (ADC) and the tag failure.
- ProductIniparib
Shares Triple-negative breast cancer (TNBC) and the tag failure.
- TrialIMpassion131
Shares Triple-negative breast cancer (TNBC) and the tag failure.
- IdeaFlush dormant cells out of bone marrow, then kill them
Shares Antibody-drug conjugate (ADC), Triple-negative breast cancer (TNBC).
- ProductPuxitatug samrotecan
Shares Antibody-drug conjugate (ADC), Triple-negative breast cancer (TNBC).